Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 21
1966 45
1967 47
1968 53
1969 35
1970 36
1971 34
1972 46
1973 68
1974 46
1975 49
1976 43
1977 37
1978 48
1979 50
1980 43
1981 55
1982 65
1983 51
1984 39
1985 38
1986 49
1987 48
1988 47
1989 48
1990 59
1991 58
1992 66
1993 56
1994 52
1995 48
1996 53
1997 60
1998 57
1999 57
2000 66
2001 56
2002 64
2003 74
2004 59
2005 66
2006 67
2007 89
2008 75
2009 89
2010 93
2011 97
2012 140
2013 106
2014 104
2015 146
2016 140
2017 106
2018 121
2019 94
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

3,358 results
Results by year
Filters applied: . Clear all
Page 1
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Chen R, et al. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25. J Clin Oncol. 2017. PMID: 28441111 Free PMC article. Clinical Trial.
[New therapy outlooks in Hodgkin lymphoma].
Rossi C, Casasnovas RO. Rossi C, et al. Bull Cancer. 2017 Feb;104(2):182-194. doi: 10.1016/j.bulcan.2016.11.005. Epub 2017 Jan 12. Bull Cancer. 2017. PMID: 28088309 Review. French.
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Evens AM, et al. J Clin Oncol. 2018 Oct 20;36(30):3015-3022. doi: 10.1200/JCO.2018.79.0139. Epub 2018 Sep 4. J Clin Oncol. 2018. PMID: 30179569 Clinical Trial.
High dose therapy for Hodgkin's disease.
Bhidayasira R, Linch D. Bhidayasira R, et al. Blood Rev. 1999 Mar;13(1):45-50. doi: 10.1016/s0268-960x(99)90022-x. Blood Rev. 1999. PMID: 10225608 Review.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Lancet. 2018 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20. Lancet. 2018. PMID: 29061295 Clinical Trial.
Treatment of Hodgkin's disease.
De Vita VT Jr, Hubbard SM, Longo DL. De Vita VT Jr, et al. J Natl Cancer Inst Monogr. 1990;(10):19-28. J Natl Cancer Inst Monogr. 1990. PMID: 2189473 Review.
[Cured from Hodgkin's disease].
Brice P. Brice P. Bull Cancer. 2002 Jul-Aug;89(7-8):666-70. Bull Cancer. 2002. PMID: 12206979 Free article. Review. French.
Chemotherapy of Hodgkin's disease.
Oza AM, Rohatiner AZ, Lister TA. Oza AM, et al. Baillieres Clin Haematol. 1991 Jan;4(1):131-56. doi: 10.1016/s0950-3536(05)80288-4. Baillieres Clin Haematol. 1991. PMID: 2039855 Review.
3,358 results
Jump to page
Feedback